產(chǎn)品名稱：SKRC39人腎乳頭狀細(xì)胞癌細(xì)胞、SKRC39人腎乳頭狀細(xì)胞癌細(xì)胞、SKRC39人腎乳頭狀細(xì)胞癌細(xì)胞、SKRC39人腎乳頭狀細(xì)胞癌細(xì)胞；


includes anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies, Monophosphoryl-lipid-A (MPLA), and an Indolamine-Dioxygenase-1 (IDO1) inhibitor. The aim of the study is, first, to rule out any major toxic eklects related to this therapy and, second, to assess